Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats

Shen,Fengyan; Meng,Yong; He,Yuhai; Huang,Bowan; Huang,Jinxin; Wang,Lu

doi:10.3892/mmr.2022.12890

Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats

Authors:
- Fengyan Shen
- Yong Meng
- Yuhai He
- Bowan Huang
- Jinxin Huang
- Lu Wang
View Affiliations

Affiliations: Department of Anesthesiology, Shenzhen Traditional Chinese Medicine Hospital, 4th Medical School of Guangzhou University of Traditional Chinese Medicine, Shenzhen, Guangdong 518033, P.R. China, Department of Rehabilitation, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150006, P.R. China
Published online on: November 3, 2022 https://doi.org/10.3892/mmr.2022.12890
Article Number: 3
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stroke is one of the leading causes of death from diseases. When the blood supply to the brain tissue is interrupted, neuronal core death occurs due to the lack of glucose and oxygen in min. Blood pressure lowering after ischemic stroke was proven to be an effective strategy to achieve neurovascular protection and reduce the risk of recurrent stroke. Astragaloside IV is a pure small molecular compound isolated from Radix Astragali, and it is well documented that astragaloside IV has neuroprotective effect on cerebral ischemia reperfusion (CIR) injury through many mechanisms, including antioxidant, anti‑inflammatory and anti‑apoptotic. The present study adopted mean arterial pressure (MAP) monitoring, neurological scoring, 2,3,5‑triphenyltetrazolium chloride staining, enzyme‑linked immuno‑sorbent assay, western blotting and other experimental methods to investigate the effect of astragaloside IV on systemic blood pressure during CIR in a middle cerebral artery occlusion animal model. It was demonstrated that astragaloside IV pretreatment significantly alleviated CIR injury as previously reported. In addition, the elevation of MAP during CIR was significantly inhibited by astragaloside IV administration. Moreover, it was revealed that the expression of Na+‑K+‑2Cl‑ cotransporter isoform 1 in the hypothalamus was inhibited and the subsequent synthesis of vasopressin was reduced by astragaloside IV pretreatment in the CIR animal model. In conclusion, astragaloside IV may alleviate CIR injury partially by lowering systemic blood pressure.

View Figures

View References

1	Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al: Heart disease and stroke statistics-2019 update: A report from the American heart association. Circulation. 139:e56–e528. 2019. View Article : Google Scholar : PubMed/NCBI
2	Stubblefield JJ and Lechleiter JD: Time to target stroke: Examining the circadian system in stroke. Yale J Biol Med. 92:349–357. 2019.PubMed/NCBI
3	Puig B, Brenna S and Magnus T: Molecular communication of a dying neuron in stroke. Int J Mol Sci. 19:28342018. View Article : Google Scholar : PubMed/NCBI
4	Feske SK: Ischemic stroke. Am J Med. 134:1457–1464. 2021. View Article : Google Scholar : PubMed/NCBI
5	Wu MY, Yiang GT, Liao WT, Tsai AP, Cheng YL, Cheng PW, Li CY and Li CJ: Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 46:1650–1667. 2018. View Article : Google Scholar : PubMed/NCBI
6	Liang D, Bhatta S, Gerzanich V and Simard JM: Cytotoxic edema: Mechanisms of pathological cell swelling. Neurosurg Focus. 22:E22007. View Article : Google Scholar : PubMed/NCBI
7	Stokum JA, Gerzanich V and Simard JM: Molecular pathophysiology of cerebral edema. J Cereb Blood Flow Metab. 36:513–538. 2016. View Article : Google Scholar : PubMed/NCBI
8	Mestre H, Du T, Sweeney AM, Liu G, Samson AJ, Peng W, Mortensen KN, Stæger FF, Bork PAR, Bashford L, et al: Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science. 367:eaax71712020. View Article : Google Scholar : PubMed/NCBI
9	Han D, Sun M, He PP, Wen LL, Zhang H and Feng J: Ischemic postconditioning alleviates brain edema after focal cerebral ischemia reperfusion in rats through down-regulation of aquaporin-4. J Mol Neurosci. 56:722–729. 2015. View Article : Google Scholar : PubMed/NCBI
10	Simao F, Ustunkaya T, Clermont AC and Feener EP: Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke. Blood. 129:2280–2290. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, de Haan R, Roos YB and Kruyt ND: Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 7:CD0078582018.PubMed/NCBI
12	Elewa HF, Kozak A, Johnson MH, Ergul A and Fagan SC: Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens. 25:855–859. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wang HL, Zhou QH, Xu MB, Zhou XL and Zheng GQ: Astragaloside IV for experimental focal cerebral ischemia: Preclinical evidence and possible mechanisms. Oxid Med Cell Longev. 2017:84243262017. View Article : Google Scholar : PubMed/NCBI
14	Jiang P, Ma D, Wang X, Wang Y, Bi Y, Yang J, Wang X and Li X: Astragaloside IV prevents obesity-associated hypertension by improving pro-inflammatory reaction and leptin resistance. Mol Cells. 41:244–255. 2018.PubMed/NCBI
15	Zhang X, Chen J, Xu P and Tian X: Protective effects of Astragaloside IV against hypoxic pulmonary hypertension. Medchemcomm. 9:1715–1721. 2018. View Article : Google Scholar : PubMed/NCBI
16	Su Z, Miao B, Xu MQ, Yang MJ, Fei SJ and Zhang JF: Protective effect of microinjection of glutamate into hypothalamus paraventricular nucleus on chronic visceral hypersensitivity in rats. Brain Res. 1747:1470482020. View Article : Google Scholar : PubMed/NCBI
17	Savić B, Murphy D and Japundžić-Žigon N: The Paraventricular Nucleus of the Hypothalamus in Control of Blood Pressure and Blood Pressure Variability. Front Physiol. 13:8589412022. View Article : Google Scholar : PubMed/NCBI
18	Kim YB, Kim YS, Kim WB, Shen FY, Lee SW, Chung HJ, Kim JS, Han HC, Colwell CS and Kim YI: GABAergic excitation of vasopressin neurons: Possible mechanism underlying sodium-dependent hypertension. Circ Res. 113:1296–1307. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kaila K, Price TJ, Payne JA, Puskarjov M and Voipio J: Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 15:637–654. 2014. View Article : Google Scholar : PubMed/NCBI
20	Virtanen MA, Uvarov P, Hubner CA and Kaila K: NKCC1, an elusive molecular target in brain development: Making sense of the existing data. Cells. 9:26072020. View Article : Google Scholar : PubMed/NCBI
21	Gorelick PB and Ruland S: Cerebral vascular disease. Dis Mon. 56:39–100. 2010. View Article : Google Scholar : PubMed/NCBI
22	Spengos K, Tsivgoulis G and Zakopoulos N: Blood pressure management in acute stroke: A long-standing debate. Eur Neurol. 55:123–135. 2006. View Article : Google Scholar : PubMed/NCBI
23	Willmot M, Leonardi-Bee J and Bath PM: High blood pressure in acute stroke and subsequent outcome: A systematic review. Hypertension. 43:18–24. 2004. View Article : Google Scholar : PubMed/NCBI
24	Gorelick PB and Aiyagari V: The management of hypertension for an acute stroke: What is the blood pressure goal? Curr Cardiol Rep. 15:3662013. View Article : Google Scholar : PubMed/NCBI
25	Aoyagi T, Koshimizu TA and Tanoue A: Vasopressin regulation of blood pressure and volume: Findings from V1a receptor-deficient mice. Kidney Int. 76:1035–1039. 2009. View Article : Google Scholar : PubMed/NCBI
26	Bankir L, Bichet DG and Morgenthaler NG: Vasopressin: Physiology, assessment and osmosensation. J Intern Med. 282:284–297. 2017. View Article : Google Scholar : PubMed/NCBI
27	Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E and Franceschini R: Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis. 11:113–118. 2001. View Article : Google Scholar : PubMed/NCBI
28	Liu X, Jin Y, Zheng H, Chen G, Tan B and Wu B: Arginine vasopressin gene expression in supraoptic nucleus and paraventricular nucleus of hypothalamous following cerebral ischemia and reperfusion. Chin Med Sci J. 15:157–161. 2000.PubMed/NCBI
29	Vakili A, Kataoka H and Plesnila N: Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 25:1012–1019. 2005. View Article : Google Scholar : PubMed/NCBI
30	Shahzad M, Shabbir A, Wojcikowski K, Wohlmuth H and Gobe GC: The antioxidant effects of Radix Astragali (Astragalus membranaceus and related species) in protecting tissues from injury and disease. Curr Drug Targets. 17:1331–1340. 2016. View Article : Google Scholar : PubMed/NCBI
31	Li L, Hou X, Xu R, Liu C and Tu M: Research review on the pharmacological effects of Astragaloside IV. Fundam Clin Pharmacol. 31:17–36. 2017. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Wu C, Gao L, Du G and Qin X: Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Adv Pharmacol. 87:89–112. 2020. View Article : Google Scholar : PubMed/NCBI
33	Kang X, Su S, Hong W, Geng W and Tang H: Research progress on the ability of Astragaloside IV to protect the brain against ischemia-reperfusion injury. Front Neurosci. 15:7559022021. View Article : Google Scholar : PubMed/NCBI
34	Tan YQ, Chen HW and Li J: Astragaloside IV: An effective drug for the treatment of cardiovascular diseases. Drug Des Devel Ther. 14:3731–3746. 2020. View Article : Google Scholar : PubMed/NCBI
35	Jin H, Jiao Y, Guo L, Ma Y, Zhao R, Li X, Shen L, Zhou Z, Kim SC and Liu J: Astragaloside IV blocks monocrotaline-induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling. Int J Mol Med. 47:595–606. 2021. View Article : Google Scholar : PubMed/NCBI
36	Jing H, Xie R, Bai Y, Duan Y, Sun C, Wang Y, Cao R, Ling Z and Qu X: The mechanism actions of Astragaloside IV prevents the progression of hypertensive heart disease based on network pharmacology and experimental pharmacology. Front Pharmacol. 12:7556532021. View Article : Google Scholar : PubMed/NCBI
37	Candelario-Jalil E, Dijkhuizen RM and Magnus T: Neuro-inflammation, stroke, blood-brain barrier dysfunction, and imaging modalities. Stroke. 53:1473–1486. 2022. View Article : Google Scholar : PubMed/NCBI
38	Yang C, Hawkins KE, Doré S and Candelario-Jalil E: Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol. 316:C135–C153. 2019. View Article : Google Scholar : PubMed/NCBI